New Imaging Modality of COVID-19 Pneumonia Developed on the Basis of Alzheimer's Disease Research
- PMID: 35955536
- PMCID: PMC9369300
- DOI: 10.3390/ijms23158405
New Imaging Modality of COVID-19 Pneumonia Developed on the Basis of Alzheimer's Disease Research
Abstract
Viral pneumonia caused by highly infectious SARS-CoV-2 poses a higher risk to older people and those who have underlying health conditions, including Alzheimer's disease. In this work we present newly designed tacrine-based radioconjugates with physicochemical and biological properties that are crucial for the potential application as diagnostic radiopharmaceuticals. A set of ten tacrine derivatives was synthesized, labelled with gallium-68 and fully characterized in the context of their physicochemical properties. Based on these results, the final two most promising radioconjugates, [68Ga]Ga-NODAGA-Bn-NH(CH2)9Tac and [68Ga]Ga-THP-NH(CH2)9Tac, were selected for biodistribution studies. The latter compound was proven to be a good inhibitor of cholinesterases with significant affinity toward the lungs, according to the biodistribution studies. On the basis of molecular modelling combined with in vitro studies, we unraveled which structural properties of the developed tacrine derivatives are crucial for high affinity toward acetylcholinesterase, whose increased levels in lung tissues in the course of coronavirus disease indicate the onset of pneumonia. The radiopharmaceutical [68Ga]Ga-THP-NH(CH2)9Tac was ultimately selected due to its increased accuracy and improved sensitivity in PET imaging of lung tissue with high levels of acetylcholinesterase, and it may become a novel potential diagnostic modality for the determination of lung perfusion, including in inflammation after COVID-19.
Keywords: COVID-19; biodistribution studies; gallium-68; molecular docking; radiopharmaceuticals; tacrine.
Conflict of interest statement
The authors declare no conflict of interest.
Figures











Similar articles
-
Synthesis, physicochemical and biological evaluation of tacrine derivative labeled with technetium-99m and gallium-68 as a prospective diagnostic tool for early diagnosis of Alzheimer's disease.Bioorg Chem. 2019 Oct;91:103136. doi: 10.1016/j.bioorg.2019.103136. Epub 2019 Jul 20. Bioorg Chem. 2019. PMID: 31374521
-
Synthesis, physicochemical and biological studies of technetium-99m labeled tacrine derivative as a diagnostic tool for evaluation of cholinesterase level.Bioorg Med Chem. 2017 Feb 1;25(3):912-920. doi: 10.1016/j.bmc.2016.12.004. Epub 2016 Dec 7. Bioorg Med Chem. 2017. PMID: 27998671
-
Preparation, Characterization, and Radiolabeling of [68Ga]Ga-NODAGA-Pamidronic Acid: A Potential PET Bone Imaging Agent.Molecules. 2020 Jun 9;25(11):2668. doi: 10.3390/molecules25112668. Molecules. 2020. PMID: 32526838 Free PMC article.
-
Therapeutic Potential of Multifunctional Tacrine Analogues.Curr Neuropharmacol. 2019;17(5):472-490. doi: 10.2174/1570159X16666180412091908. Curr Neuropharmacol. 2019. PMID: 29651948 Free PMC article. Review.
-
Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease.J Enzyme Inhib Med Chem. 2017 Dec;32(1):572-587. doi: 10.1080/14756366.2016.1210139. J Enzyme Inhib Med Chem. 2017. PMID: 28133981 Free PMC article. Review.
References
-
- Sheng N., Xue-Ping M., Pang S.-Y., Song Q.-X., Zou B.-J., Zhou G.-H. Research Progress of Nucleic Acid Detection Technology Platforms for New Coronavirus SARS-CoV-2. Chin. J. Anal. Chem. 2020;48:1279–1287. doi: 10.1016/S1872-2040(20)60048-2. - DOI
-
- Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous